Prodigiosin Sensitizes Sensitive and Resistant Urothelial Carcinoma Cells to Cisplatin Treatment

Prodigiosin Sensitizes Sensitive and Resistant Urothelial Carcinoma Cells to Cisplatin Treatment

Cisplatin-based treatment is the standard of care therapy for urothelial carcinomas. However, complex cisplatin resistance mechanisms limit the success of this approach. Both apoptosis and autophagy have been shown to contribute to this resistance. Prodigiosin, a secondary metabolite from various ba...

Full description

Bibliographic Details
Main Authors: Lena Berning, David Schlütermann, Annabelle Friedrich, Niklas Berleth, Yadong Sun, Wenxian Wu, María José Mendiburo, Jana Deitersen, Hannah U. C. Brass, Margaretha A. Skowron, Michèle J. Hoffmann, Günter Niegisch, Jörg Pietruszka, Björn Stork
Format: Article
Language:English
Published: MDPI AG 2021-02-01
Series:Molecules
Subjects:
prodigiosin
urothelial carcinoma
cisplatin
chemoresistance
autophagy
apoptosis
Online Access:https://www.mdpi.com/1420-3049/26/5/1294

Internet

https://www.mdpi.com/1420-3049/26/5/1294

Similar Items